Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404107 | 0.78 | ALOX15 (0.38) | TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL6863765 | 0.77 | TDP1 (0.40) | TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL9136836 | 0.76 | HCAR2 (0.41) | — | |
| SCHEMBL1828772 | 0.74 | ALOX15 (0.36) | TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL2048611 | 0.72 | TDP1 (0.36) | TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL8812874 | 0.72 | TDP1 (0.43) | TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL28120698 | 0.71 | HCAR2 (0.40) | TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL3716837 | 0.71 | HCAR2 (0.50) | TDP1SMN1; SMN2 | |
| SCHEMBL646453 | 0.71 | HCAR2 (0.50) | TDP1SMN1; SMN2 | |
| SCHEMBL6008457 | 0.71 | EGLN1 (0.39) | TDP1SMN1; SMN2SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288170-A1 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS | UNIVERSITY OF WASHINGTON (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011132084-A2 | THERAPEUTIC REGIMEN AND METHOD FOR TREATING OR AMELIORATING VISUAL DISORDERS ASSOCIATED WITH AN ENDOGENOUS RETINOID DEFICIENCY | QLT INC. (CA) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257266-A1 | Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated | QLT, INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-7951841-B2 | 9-Cis- or 11-cis-retinyl succinate, citrate, ketoglutarate, fumarate, malate or oxaloacetate; administering to vertebrate having an endogenous retinoid deficiency; vision defects; 9-cis-retinyl acetate or 9-cis-retinyl succinate; photoreceptor stabilizers; macular degeneration | UNIVERSITY OF WASHINGTON (US) | 2011-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257266-A1 | Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated | RBP4, RBP1, ALDH1A2 | TDP1 1787/4885SMN1; SMN2 148/4885SLC22A6 2470/4885 |
| US-20110288170-A1 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS | NR2E3, ALDH1A2, RARB | TDP1 3700/4885SMN1; SMN2 1509/4885SLC22A6 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.